Table 2.
Pooled COVID-19 Vaccine Effectiveness against lab-confirmed COVID-19 hospitalization for partially and fully vaccinated study participants, by vaccine product in use and by age group. Latin America, 2021.
| Vaccine | Age group | Analytic Method | # Vaccinated | # Unvaccinated | Partially vaccinated | Fully vaccinated |
|---|---|---|---|---|---|---|
| Sputnik V | 80+ | Adjusteda unmatched TND | 30 | 2701 | 31 (−269, 87) | 3 (−474, 84) |
| Sputnik V | 80+ | Unadjusted unmatched TND | 30 | 2701 | 83 (38, 95) | 85 (48, 96) |
| Sputnik V | 65–79 | Adjusted unmatched TND | 56 | 9337 | 15 (−90, 62) | 59 (−40, 88) |
| Sputnik V | 65–79 | Unadjusted unmatched TND | 56 | 9337 | 74 (51, 86) | 89 (69, 96) |
| Sputnik V | 50–64 | Adjusted unmatched TND | 37 | 18,198 | 14 (−129, 68) | 21 (−472, 89) |
| Sputnik V | 50–64 | Unadjusted unmatched TND | 37 | 18,198 | 60 (10, 82) | 80 (−21, 97) |
| Sputnik V | 18–49 | Adjusted unmatched TND | 22 | 24,938 | 77 (24, 93) | −65 (−1627, 84) |
| Sputnik V | 18–49 | Unadjusted unmatched TND | 22 | 24,938 | 93 (81, 98) | 47 (−407, 95) |
| mRNA-1273 | 80+ | Adjusted unmatched TND | 6 | 2701 | −37 (−1733, 90) | 100 (NE) |
| mRNA-1273 | 80+ | Unadjusted unmatched TND | 6 | 2701 | 79 (−104, 98) | 100 (NE) |
| mRNA-1273 | 65–79 | Adjusted unmatched TND | 16 | 9337 | 100 (-Inf, 100) | 22 (−550, 91) |
| mRNA-1273 | 65–79 | Unadjusted unmatched TND | 16 | 9337 | 100 (NE) | 97 (79, 100) |
| mRNA-1273 | 50–64 | Adjusted unmatched TND | 17 | 18,198 | 66 (−188, 96) | 100 (NE) |
| mRNA-1273 | 50–64 | Unadjusted unmatched TND | 17 | 18,198 | 98 (87, 100) | 100 (NE) |
| mRNA-1273 | 18–49 | Adjusted unmatched TND | 75 | 24,938 | 25 (−74, 67) | 100 (NE) |
| mRNA-1273 | 18–49 | Unadjusted unmatched TND | 75 | 24,938 | 97 (94, 99) | 100 (NE) |
| CoronaVac | 80+ | Adjusted unmatched TND | 4161 | 2701 | 0 (−23, 18) | 30 (18, 40) |
| CoronaVac | 80+ | Unadjusted unmatched TND | 4161 | 2701 | −33 (−57, −12) | 25 (17, 33) |
| CoronaVac | 65–79 | Adjusted unmatched TND | 8044 | 9337 | 20 (6, 31) | 32 (23, 40) |
| CoronaVac | 65–79 | Unadjusted unmatched TND | 8044 | 9337 | −3 (−16, 9) | 54 (51, 57) |
| CoronaVac | 50–64 | Adjusted unmatched TND | 1307 | 18,198 | 17 (−9, 36) | 53 (43, 62) |
| CoronaVac | 50–64 | Unadjusted unmatched TND | 1307 | 18,198 | 44 (30, 56) | 83 (81, 86) |
| CoronaVac | 18–49 | Adjusted unmatched TND | 1385 | 24,938 | 16 (−5, 33) | 48 (38, 57) |
| CoronaVac | 18–49 | Unadjusted unmatched TND | 1385 | 24,938 | 47 (36, 56) | 77 (73, 80) |
| ChAdOx1 | 80+ | Adjusted unmatched TND | 2292 | 2701 | 16 (−2, 31) | 48 (35, 58) |
| ChAdOx1 | 80+ | Unadjusted unmatched TND | 2292 | 2701 | −52 (−76, −31) | 45 (37, 52) |
| ChAdOx1 | 65–79 | Adjusted unmatched TND | 2109 | 9337 | 49 (39, 56) | 61 (53, 68) |
| ChAdOx1 | 65–79 | Unadjusted unmatched TND | 2109 | 9337 | 45 (38, 52) | 84 (82, 86) |
| ChAdOx1 | 50–64 | Adjusted unmatched TND | 4384 | 18,198 | 49 (42, 55) | 64 (57, 70) |
| ChAdOx1 | 50–64 | Unadjusted unmatched TND | 4384 | 18,198 | 54 (49, 58) | 90 (89, 91) |
| ChAdOx1 | 18–49 | Adjusted unmatched TND | 2099 | 24,938 | 39 (30, 47) | 68 (58, 75) |
| ChAdOx1 | 18–49 | Unadjusted unmatched TND | 2099 | 24,938 | 49 (43, 55) | 91 (89, 93) |
| BNT162b2 | 80+ | Adjusted unmatched TND | 44 | 2701 | 33 (−76, 74) | 65 (−77, 93) |
| BNT162b2 | 80+ | Unadjusted unmatched TND | 44 | 2701 | 62 (12, 83) | 93 (69, 98) |
| BNT162b2 | 65–79 | Adjusted unmatched TND | 228 | 9337 | 27 (−30, 59) | 80 (64, 89) |
| BNT162b2 | 65–79 | Unadjusted unmatched TND | 228 | 9337 | 79 (67, 87) | 98 (96, 99) |
| BNT162b2 | 50–64 | Adjusted unmatched TND | 810 | 18,198 | 55 (43, 65) | 87 (80, 91) |
| BNT162b2 | 50–64 | Unadjusted unmatched TND | 810 | 18,198 | 72 (66, 77) | 98 (97, 99) |
| BNT162b2 | 18–49 | Adjusted unmatched TND | 1180 | 24,938 | 62 (54, 68) | 70 (58, 78) |
| BNT162b2 | 18–49 | Unadjusted unmatched TND | 1180 | 24,938 | 80 (77, 83) | 95 (94, 96) |
| Ad26.COV2.S | 80+ | Adjusted unmatched TND | 1 | 2701 | 100 (NE) | |
| Ad26.COV2.S | 80+ | Unadjusted unmatched TND | 1 | 2701 | 100 (NE) | |
| Ad26.COV2.S | 65–79 | Adjusted unmatched TND | 4 | 9337 | 19 (−714, 92) | |
| Ad26.COV2.S | 65–79 | Unadjusted unmatched TND | 4 | 9337 | 28 (−592, 93) | |
| Ad26.COV2.S | 50–64 | Adjusted unmatched TND | 20 | 18,198 | 77 (40, 91) | |
| Ad26.COV2.S | 50–64 | Unadjusted unmatched TND | 20 | 18,198 | 89 (73, 95) | |
| Ad26.COV2.S | 18–49 | Adjusted unmatched TND | 125 | 24,938 | 54 (30, 69) | |
| Ad26.COV2.S | 18–49 | Unadjusted unmatched TND | 125 | 24,938 | 69 (55, 78) |
NE = not estimated.
a
Adjusted for continuous age, sex, secondary administrative unit location of residence, date of hospitalization grouped into categorical epiweeks, presence of 1 or more comorbidities, and study site country.